Research compounds
Kisspeptin
Kisspeptin-10 / KP-10
A hormone produced in the hypothalamus that plays a master role in triggering puberty and regulating reproductive hormones (LH and FSH).
Also known as: Metastin, KISS1
- Status
- Kisspeptin is in Phase 2 clinical trials and not approved.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- ~28 minutes
- How it's taken
- IV or subcutaneous injection (clinical settings)
- Mechanism
- Reproductive axis (GnRH / kisspeptin / oxytocin)
- Pathways
- GnRH
How Kisspeptin works
Binds to GPR54 receptors in the brain, which triggers the release of gonadotropin-releasing hormone (GnRH). This cascade activates the entire reproductive hormone axis.
What research has looked at
- Diagnostic tool for reproductive disorders
- May restore hormone function in deficiency
- Studied for IVF support
- Potential in hypogonadism treatment
- No desensitization seen with pulsatile dosing
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Hot flashes
- Headache
- Nausea
- Abdominal discomfort
- Research use only — not approved
Sources
- PubMed research on kisspeptin GnRH reproductive hormone · NIH · National Library of Medicine
- Active clinical trials for kisspeptin · U.S. National Library of Medicine
- DrugBank record for kisspeptin · DrugBank
Track Kisspeptin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Kisspeptin FAQ
What is Kisspeptin?
A hormone produced in the hypothalamus that plays a master role in triggering puberty and regulating reproductive hormones (LH and FSH).
How does Kisspeptin work?
Binds to GPR54 receptors in the brain, which triggers the release of gonadotropin-releasing hormone (GnRH). This cascade activates the entire reproductive hormone axis.
Is Kisspeptin FDA approved?
No. Kisspeptin is in Phase 2 clinical trials and not approved. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Kisspeptin?
Reported half-life: ~28 minutes.
How is Kisspeptin taken?
IV or subcutaneous injection (clinical settings).
What side effects have been reported with Kisspeptin?
Reported in the sources: Hot flashes; Headache; Nausea; Abdominal discomfort; Research use only — not approved.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.